Avoiding disclosure of sensitive information on EOBs could make coverage more appealing to young people.
Privacy issues can act as a barrier for uninsured young adults seeking health coverage, experts say. Under the Affordable Care Act (ACA), young adults can stay on their parents' policy until age 26. For those considering joining a family plan as a dependent, patient privacy could be a factor in their decision. For this reason, plans might benefit from updating their Explaination of Benefit (EOB) statements and dispersing them in a way to ensure more privacy.
“A lot of young adults live at home, and if they’re going to become dependents then they’re going to be on their parents’ coverage,” says Ted Goldman, lead author of the Health Policy brief Young Adults and the Affordable Care Act. “You don’t always want your mother getting your mail and opening it up to see that you had some medical procedure until you tell her about it.”
Sending information directly to the patient, not the subscriber, and avoiding disclosure of sensitive information on EOBs could make coverage more appealing to young people.
The enrollment of young adults is vital to the long-term survival of the exchanges, industry experts say. Young and healthy beneficiaries are needed to balance the risk pool so premiums can stay low and a death spiral is avoided.
Look for more tips on how to attract young invincibles in our February issue.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
Extending the Capabilities of the EHR Through Automation
August 2nd 2023Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More